Phibro Animal Health Corporation (PAHC) Key Metrics
PAHC valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.58B
- Enterprise value
- $2.09B
- P/E (TTM)
- 16.0 10-yr median 22.2
- Forward P/E
- 13.8
- PEG ratio
- 1.68
- Price / sales
- 1.0 10-yr median 1.1
- Price / book
- 3.6 10-yr median 4.3
- EV / EBITDA
- 9.0 10-yr median 13.6
- Dividend yield
- 0.64% $0.48 a year
- Beta
- 0.42
PAHC key metrics, FY2017–FY2026
Fiscal year ended June 30, 2026 · U.S. dollarsPAHC valuation Price multiples at each fiscal year-end price.
PAHC returns How much profit the business earns on the capital it uses.
PAHC per-share figures Results divided by the shares outstanding at year-end.
PAHC financial health Debt, liquidity and how easily interest is covered.
PAHC efficiency & capital use Working capital cycle and where the cash goes.
PAHC valuation history
PAHC returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
PAHC debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
PAHC cash returned to shareholders
PAHC price vs earnings per share
PAHC key metrics
FY2017–FY2026| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $1.29B | $1.04B | $679.6M | $554.9M | $774.8M | $1.17B | $1.06B | $1.29B | $1.86B | $1.48B |
| Enterprise value | $1.99B | $1.72B | $1.09B | $983.6M | $1.15B | $1.50B | $1.38B | $1.53B | $2.09B | $1.74B |
| P/E ratio | 12.9 | 21.5 | 281.3 | 17.0 | 15.8 | 21.5 | 31.7 | 23.5 | 28.7 | 22.9 |
| Price / sales | 0.8 | 0.8 | 0.7 | 0.6 | 0.8 | 1.4 | 1.3 | 1.6 | 2.3 | 1.9 |
| Price / book | 3.3 | 3.6 | 2.6 | 2.0 | 3.0 | 4.9 | 5.7 | 6.0 | 10.1 | 9.8 |
| Price / free cash flow | 130.5 | 24.8 | 14.7 | — | — | 61.6 | 42.0 | 74.5 | 36.2 | 19.1 |
| Price / operating cash flow | 18.7 | 13.0 | 7.8 | 41.7 | 24.5 | 24.2 | 17.9 | 27.3 | 26.6 | 15.1 |
| EV / sales | 1.3 | 1.3 | 1.1 | 1.0 | 1.2 | 1.8 | 1.7 | 1.9 | 2.6 | 2.3 |
| EV / EBITDA | 8.4 | 11.7 | 15.8 | 9.3 | 9.9 | 13.6 | 13.6 | 13.6 | 16.6 | 14.0 |
| EV / free cash flow | 202.1 | 41.2 | 23.5 | — | — | 79.2 | 54.7 | 88.7 | 40.7 | 22.4 |
| Earnings yield | 7.7% | 4.6% | 0.4% | 5.9% | 6.3% | 4.6% | 3.2% | 4.2% | 3.5% | 4.4% |
| Free cash flow yield | 0.8% | 4.0% | 6.8% | −6.9% | −0.7% | 1.6% | 2.4% | 1.3% | 2.8% | 5.2% |
| Dividend yield | 1.5% | 1.9% | 2.9% | 3.5% | 2.5% | 1.7% | 1.8% | 1.4% | 0.9% | 1.1% |
| Shareholder yield (dividends + buybacks) | 1.5% | 1.9% | 2.9% | 3.5% | 2.5% | 1.7% | 1.8% | 1.4% | 0.9% | 1.1% |
| Share price at fiscal year-end | $31.40 | $25.54 | $16.77 | $13.70 | $19.13 | $28.88 | $26.27 | $31.77 | $46.05 | $37.05 |
| Per share | ||||||||||
| Revenue per share | $37.03 | $31.85 | $25.11 | $24.14 | $23.27 | $20.58 | $19.76 | $20.43 | $20.30 | $19.11 |
| Earnings per share | $2.43 | $1.19 | $0.06 | $0.81 | $1.21 | $1.34 | $0.83 | $1.35 | $1.61 | $1.61 |
| Operating cash flow per share | $1.68 | $1.97 | $2.16 | $0.33 | $0.78 | $1.19 | $1.47 | $1.16 | $1.73 | $2.46 |
| Free cash flow per share | $0.24 | $1.03 | $1.14 | −$0.95 | −$0.13 | $0.47 | $0.62 | $0.43 | $1.27 | $1.94 |
| Cash per share | $2.00 | $1.89 | $2.83 | $2.01 | $2.25 | $2.30 | $2.26 | $2.01 | $1.96 | $1.40 |
| Book value per share | $9.40 | $7.02 | $6.33 | $6.97 | $6.48 | $5.89 | $4.65 | $5.33 | $4.58 | $3.78 |
| Tangible book value per share | $7.20 | $4.66 | $3.88 | $4.30 | $3.59 | $3.05 | $1.59 | $3.48 | $2.61 | $1.81 |
| Dividends per share | $0.47 | $0.48 | $0.48 | $0.48 | $0.48 | $0.48 | $0.48 | $0.46 | $0.40 | $0.40 |
| Capex per share | $1.44 | $0.94 | $1.02 | $1.28 | $0.91 | $0.72 | $0.84 | $0.74 | $0.46 | $0.52 |
| Debt per share | $19.24 | $18.71 | $12.97 | $12.59 | $11.62 | $10.54 | $10.14 | $8.05 | $7.73 | $7.83 |
| Shares outstanding | 41.0M | 40.7M | 40.5M | 40.5M | 40.5M | 40.5M | 40.5M | 40.5M | 40.4M | 40.0M |
| Change in shares outstanding | +0.7% | +0.4% | +0.0% | +0.0% | 0.0% | 0.0% | −0.1% | +0.3% | +1.0% | 0.0% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 29.7% | 17.8% | 0.9% | 12.0% | 19.6% | 25.5% | 16.6% | 27.3% | 38.6% | 53.5% |
| Return on invested capital (ROIC) | 14.0% | 9.6% | 3.9% | 6.4% | 8.8% | 11.3% | 8.6% | 12.8% | 17.6% | 19.2% |
| Return on assets (ROA) | 7.0% | 4.1% | 0.2% | 3.4% | 5.5% | 6.7% | 4.4% | 7.8% | 10.0% | 10.5% |
| Return on tangible assets | 7.1% | 3.8% | 0.3% | 3.8% | 6.0% | 7.5% | 5.1% | 8.4% | 11.0% | 11.9% |
| Free cash flow margin | 0.6% | 3.2% | 4.6% | −3.9% | −0.6% | 2.3% | 3.2% | 2.1% | 6.3% | 10.1% |
| Income quality (OCF / net income) | 0.69 | 1.66 | 36.26 | 0.41 | 0.64 | 0.89 | 1.77 | 0.86 | 1.08 | 1.52 |
| Financial health | ||||||||||
| Total debt | $788.8M | $761.6M | $525.5M | $510.0M | $470.5M | $426.7M | $410.7M | $326.2M | $312.4M | $313.1M |
| Cash & short-term investments | $82.0M | $77.0M | $114.6M | $81.3M | $91.2M | $93.2M | $91.3M | $81.6M | $79.2M | $56.1M |
| Net debt | $706.8M | $684.5M | $410.8M | $428.7M | $379.2M | $333.5M | $319.4M | $244.6M | $233.2M | $257.1M |
| Debt / equity | 2.05 | 2.67 | 2.05 | 1.81 | 1.79 | 1.79 | 2.18 | 1.51 | 1.69 | 2.07 |
| Debt / assets | 0.53 | 0.56 | 0.53 | 0.52 | 0.50 | 0.51 | 0.52 | 0.45 | 0.47 | 0.50 |
| Net debt / EBITDA | 2.99 | 4.66 | 5.95 | 4.04 | 3.24 | 3.03 | 3.14 | 2.17 | 1.85 | 2.07 |
| Current ratio | 2.96 | 2.76 | 2.94 | 3.33 | 2.97 | 3.04 | 2.87 | 3.02 | 2.90 | 3.14 |
| Quick ratio | 1.27 | 1.25 | 1.64 | 1.75 | 1.61 | 1.72 | 1.62 | 1.74 | 1.66 | 1.75 |
| Interest coverage | 4.2 | 3.3 | 2.4 | 4.0 | 6.5 | 7.2 | 4.8 | 5.4 | 8.3 | 6.6 |
| Working capital | $619.0M | $517.1M | $396.8M | $409.7M | $375.4M | $334.8M | $294.6M | $311.9M | $272.2M | $247.9M |
| Invested capital | $1.09B | $970.2M | $667.5M | $711.2M | $641.7M | $572.0M | $507.6M | $460.6M | $418.2M | $408.2M |
| Tangible asset value | $295.4M | $189.6M | $157.1M | $174.2M | $145.4M | $123.6M | $64.5M | $141.2M | $105.6M | $72.6M |
| Net current asset value | −$180.3M | −$264.6M | −$124.5M | −$103.2M | −$103.0M | −$103.9M | −$144.1M | −$44.5M | −$71.3M | −$108.6M |
| Graham number | $22.68 | $13.69 | $2.91 | $11.24 | $13.31 | $13.34 | $9.31 | $12.72 | $12.86 | $11.72 |
| Graham net-net per share | −$14.32 | −$14.86 | −$8.66 | −$8.55 | −$7.99 | −$7.19 | −$7.69 | −$5.20 | −$5.36 | −$6.03 |
| Capital allocation | ||||||||||
| Dividends paid | $19.5M | $19.4M | $19.4M | $19.4M | $19.4M | $19.4M | $19.4M | $18.6M | $16.1M | $15.8M |
| Share buybacks (net) | — | — | — | — | — | — | — | $0 | $0 | $0 |
| Dividend payout ratio | 19.5% | 40.3% | 804.7% | 59.6% | 39.5% | 35.7% | 57.9% | 34.0% | 24.8% | 24.5% |
| Dividends + buybacks / free cash flow | 197.3% | 46.5% | 41.9% | — | — | 102.3% | 76.7% | 107.6% | 31.2% | 20.4% |
| Capex / revenue | 3.9% | 3.0% | 4.1% | 5.3% | 3.9% | 3.5% | 4.3% | 3.6% | 2.3% | 2.7% |
| Capex / operating cash flow | 85.7% | 47.8% | 47.1% | 389.1% | 117.0% | 60.7% | 57.4% | 63.4% | 26.5% | 21.2% |
| Capex / depreciation | 1.15 | 0.84 | 1.14 | 1.52 | 1.13 | 0.92 | 1.05 | 1.08 | 0.69 | 0.80 |
| Stock-based compensation / revenue | 0.1% | 0.1% | 0.0% | −1.1% | 0.0% | 0.1% | 0.3% | 0.3% | 0.0% | −15.9% |
| R&D / revenue | — | 1.8% | 2.9% | 2.5% | 2.2% | 2.1% | 1.7% | 1.5% | 1.2% | 1.2% |
| SG&A / revenue | 20.6% | 22.3% | 25.5% | 23.2% | 21.9% | 23.6% | 23.5% | 21.9% | 20.5% | 19.7% |
| Efficiency | ||||||||||
| Days sales outstanding | 56.1 | 56.0 | 59.7 | 61.6 | 60.7 | 59.9 | 65.1 | 65.0 | 58.2 | 59.6 |
| Days of inventory on hand | 177.7 | 144.6 | 140.8 | 144.1 | 132.1 | 134.1 | 132.6 | 122.0 | 112.0 | 116.3 |
| Days payables outstanding | 48.2 | 45.6 | 41.3 | 45.5 | 45.6 | 43.7 | 46.8 | 43.0 | 38.4 | 41.4 |
| Cash conversion cycle (days) | 185.7 | 155.0 | 159.2 | 160.2 | 147.2 | 150.3 | 151.0 | 143.9 | 131.8 | 134.5 |
| Receivables turnover | 6.50 | 6.52 | 6.11 | 5.93 | 6.01 | 6.10 | 5.61 | 5.62 | 6.27 | 6.12 |
| Payables turnover | 7.57 | 8.01 | 8.84 | 8.02 | 8.01 | 8.36 | 7.80 | 8.49 | 9.50 | 8.82 |
| Inventory turnover | 2.05 | 2.52 | 2.59 | 2.53 | 2.76 | 2.72 | 2.75 | 2.99 | 3.26 | 3.14 |
| Asset turnover | 1.06 | 1.11 | 1.04 | 1.03 | 1.06 | 1.03 | 1.06 | 1.18 | 1.27 | 1.24 |
| Average receivables | $233.4M | $198.7M | $166.5M | $165.0M | $156.7M | $136.7M | $142.8M | $147.4M | $130.8M | $124.8M |
| Average payables | $132.8M | $111.9M | $79.7M | $84.7M | $82.0M | $67.2M | $69.6M | $66.3M | $58.2M | $58.5M |
| Average inventory | $489.7M | $355.2M | $271.7M | $268.4M | $237.7M | $206.5M | $197.5M | $188.2M | $169.7M | $164.5M |
| Intangibles / total assets | 6.0% | 7.1% | 10.1% | 11.1% | 12.6% | 13.7% | 15.8% | 10.3% | 11.8% | 12.6% |
Computed from PAHC's annual financial statements (latest annual report filed August 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
PAHC valuation and financial ratios
At the end of fiscal 2026 (June 30, 2026), Phibro Animal Health traded at 12.9 times earnings, against a 10-year median of 22.2. Based on the latest twelve months, the trailing P/E is 16.0 and the forward P/E is 13.8. Phibro Animal Health earned a return on equity of 29.7% and a return on invested capital of 14.0% in fiscal 2026. It ended the year with $788.8 million of debt and $82.0 million in cash and short-term investments, net debt of $706.8 million. It returned $19.5 million to shareholders: $19.5 million in dividends and $0 in share buybacks, 197% of free cash flow.
See the PAHC income statement, the PAHC chart for price history, or the PAHC stock overview for the latest quote and news.
PAHC key metrics FAQ
What is Phibro Animal Health's P/E ratio?
Phibro Animal Health's trailing P/E ratio is 16.0 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 13.8. At the end of fiscal 2026 it was 12.9, compared with a 10-year median of 22.2.
What is Phibro Animal Health's EV/EBITDA?
Phibro Animal Health's enterprise value was 8.4 times EBITDA at the end of fiscal 2026 (enterprise value $2.0 billion, EBITDA $236.5 million); the current EV/EBITDA is 9.0.
What is Phibro Animal Health's return on equity?
Phibro Animal Health's return on equity (ROE) was 29.7% in fiscal 2026: net income of $99.7 million on average shareholders' equity of $335.6 million.
What is Phibro Animal Health's ROIC?
Phibro Animal Health's return on invested capital was 14.0% in fiscal 2026, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Phibro Animal Health have?
Phibro Animal Health had total debt of $788.8 million at the end of fiscal 2026, a debt-to-equity ratio of 2.05 and $706.8 million of net debt (2.99 times EBITDA).
What is Phibro Animal Health's dividend yield?
Phibro Animal Health's forward dividend yield is 0.64%. Phibro Animal Health paid $19.5 million in dividends in fiscal 2026 ($0.47 per share), a payout ratio of 19.5%.
What is Phibro Animal Health's free cash flow yield?
Phibro Animal Health generated $9.9 million of free cash flow in fiscal 2026, a free cash flow yield of 0.8% on its market value at year-end ($1.3 billion).
What is Phibro Animal Health's current ratio?
Phibro Animal Health's current ratio was 2.96 at the end of fiscal 2026: current assets were 2.96 times current liabilities.